TREATMENT OF CHRONIC PURULENT HIDRADENITIS (CLINICAL CASE)

TREATMENT OF CHRONIC PURULENT HIDRADENITIS (CLINICAL CASE)

Authors

  • TAMAR EBANOIDZE
  • GIORGI DURGLISHVILI
  • LELA BERIDZE
  • NINO GRDZELIDZE

DOI:

https://doi.org/10.52340/jecm.2023.03.18

Keywords:

Hidradenitis, chronic, treatment, Isotretinoin

Abstract

Hidradenitis suppurativa is a chronic, recurrent disease associated with inflammation of the apocrine sweat glands. The inflammatory process in the apocrine sweat glands spreads from the hair follicle and develops mainly in the armpits, in the groin area, around the nipple and the anus. The treatment of the disease depends on the stage. The goal of treating hidradenitis suppurativa is to prevent new lesions, reduce inflammation, and remove holes and pits. The purpose of our observation was to evaluate the use of isotretinoin in the treatment of chronic suppurative hidradenitis. For hidradenitis suppurativa, we chose isotretinoin in the ratio of 0.5 mg/kg of the body weight in 2 doses, which was 20 mg twice daily for 4 months or until full improvement. Our observation showed that isotretinoin is successfully used in the treatment of chronic suppurative hidradenitis as an alternative remedy.

Downloads

Download data is not yet available.

References

Jonette E. Keri MD, PhD, University of Miami, Miller School of Medicine. 2022

Thomas P Habif. Skin disease Diagnosis and treatment. 2016

Burova SA, Borodulina KS. Hydradenitis suppurativa: issues of pathogenesis, rating scales, treatment. Overview (part 2) Klinicheskaya Dermatologiya i Venerologiya. 2019;18(3):265 269.

Downloads

Published

2023-09-18

How to Cite

EBANOIDZE, T., DURGLISHVILI, G., BERIDZE, L., & GRDZELIDZE, N. (2023). TREATMENT OF CHRONIC PURULENT HIDRADENITIS (CLINICAL CASE). Experimental and Clinical Medicine Georgia, (3). https://doi.org/10.52340/jecm.2023.03.18

Issue

Section

Articles

Most read articles by the same author(s)

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.

Loading...